Linical Co., Ltd. AI Stock Analysis
Want to see JP:2183 full AI Analyst Report?
Linical Co., Ltd. (2183) AI Stock Analysis
Linical Co., Ltd.
(TSE/TYO:2183)
Linical scores poorly, driven primarily by a sharply deteriorating financial profile: three consecutive years of revenue decline, collapsed gross margins, a projected ¥3.3 billion net loss, negative EBITDA, and negative operating and free cash flow that is rapidly eroding an already halved equity base. Technicals reinforce the caution, with the stock trading below all major moving averages and a negative MACD, though a low Stochastic reading hints at near-term oversold conditions. Valuation provides little support — earnings are negative, and the 4.06% dividend yield is not covered by current cash generation, raising sustainability risk. Modest positives include some debt reduction, still-positive equity, and low beta. Earnings call and corporate event components were excluded due to missing data, with their weight redistributed across the remaining factors.
Linical Co., Ltd. (2183) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 4.34B
- Dividend Yield
- 4.12%
- Average Volume (3M)
- 52.63K
- Price to Earnings (P/E)
- -1.2
- Beta (1Y)
- 0.58
- Revenue Growth
- -23.55%
- EPS Growth
- -205.65%
- Country
- Japan
- Employees
- 577
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Specialty Business Services
Linical Co., Ltd. Business Overview & Revenue Model
Company Description
Linical Co., Ltd., a global contract research organization provides full spectrum of drug development services to pharmaceutical companies worldwide. The company offers drug development consulting services, such as market analysis of products in deve...
How the Company Makes Money
Linical makes money primarily by selling outsourced clinical development services to pharmaceutical, biotechnology, and related life-science customers. Revenue is generally earned under service contracts where Linical is paid fees for executing defin...
Linical Co., Ltd. Financial Statement Overview
Summary
Financials are in severe distress. Revenue has fallen for three straight years (-31% cumulatively, -14.5% most recently), gross margins have collapsed from ~33% to ~8.7%, and the company is projected to post a ¥3.3 billion net loss (-38.4% net margin) with negative EBITDA. Operating cash flow has swung from +¥1.9 billion to -¥1.5 billion, with free cash flow at -¥1.6 billion, meaning the business is now consuming reserves. The balance sheet offers only a thin cushion: equity has been halved to ¥4.0 billion, debt-to-equity has risen to 0.57, and ROE is -83.7%. Modest offsets include some deleveraging (total debt down to ¥2.3 billion) and still-positive equity, but the trajectory points to possible dilution or restructuring without a turnaround.
Income Statement
15Very NegativeBalance Sheet
30NegativeCash Flow
18Very Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.95B | 8.67B | 10.44B | 12.31B | 12.52B | 11.56B |
| Gross Profit | 119.13M | 753.13M | 2.01B | 3.43B | 3.84B | 3.34B |
| EBITDA | -2.21B | -1.54B | -46.50M | 1.25B | 1.76B | 1.54B |
| Net Income | -3.79B | -3.33B | -539.10M | 338.27M | 1.00B | 790.49M |
Balance Sheet | ||||||
| Total Assets | 11.06B | 12.00B | 16.78B | 18.54B | 17.46B | 15.72B |
| Cash, Cash Equivalents and Short-Term Investments | 4.68B | 5.20B | 7.04B | 7.47B | 7.04B | 5.99B |
| Total Debt | 2.04B | 2.25B | 2.42B | 3.00B | 3.63B | 4.19B |
| Total Liabilities | 7.85B | 8.02B | 9.52B | 10.30B | 9.88B | 9.17B |
| Stockholders Equity | 3.21B | 3.98B | 7.25B | 8.24B | 7.58B | 6.54B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -1.55B | 602.21M | 1.08B | 1.85B | 1.64B |
| Operating Cash Flow | 0 | -1.52B | 605.10M | 1.11B | 1.86B | 1.68B |
| Investing Cash Flow | 0 | -1.96M | -54.93M | -70.47M | -31.79M | -32.14M |
| Financing Cash Flow | 0 | -513.25M | -939.22M | -960.92M | -957.33M | -951.55M |
Linical Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2183, the sentiment is Negative. The current price of 194.00 is below the 20-day moving average (MA) of 197.55, below the 50-day MA of 200.90, and below the 200-day MA of 232.89, indicating a bearish trend. The MACD of -1.92 indicates Positive momentum. The RSI at 38.55 is Neutral, neither overbought nor oversold. The STOCH value of 49.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:2183.
Linical Co., Ltd. Peers Comparison
Overall Rating
JP:489156Neutral
JP:497845Neutral
JP:234244Neutral
JP:218341Neutral
JP:237038Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 56Neutral | JPY 6.54B | -5.90 | ― | ― | ― | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | JPY 11.75B | -24.37 | ― | ― | -8.23% | -48.10% | |
| 44Neutral | JPY 3.02B | -156.08 | ― | ― | 8.53% | 97.93% | |
| 41Neutral | JPY 4.38B | -1.20 | ― | 4.12% | -23.55% | -205.65% | |
| 38Underperform | JPY 4.55B | -2.95 | ― | ― | 1.41% | 1.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:2183 | Linical Co., Ltd. | 194.00 | -97.98 | -33.56% | |
| JP:2342 | Trans Genic Inc. | 179.00 | -31.00 | -14.76% | |
| JP:2370 | MEDINET Co., Ltd. | 16.00 | -17.00 | -51.52% | |
| JP:4891 | TMS Co., Ltd. | 135.00 | -2.00 | -1.46% | |
| JP:4978 | ReproCELL Inc. | 110.00 | -51.00 | -31.68% |
Linical Co., Ltd. Corporate Events
Linical Reports Six-Month Sales Decline and Larger Losses
Linical Co., Ltd., listed on the Tokyo Stock Exchange, reported consolidated net sales of ¥3,739 million for the six months ended September 30, 2026, down 23.0% year on year. Operating loss was ¥1,280 million, ordinary loss was ¥1,360 million, and lo...
Linical Wins $20 Million U.S. Biotech Order as FDA Environment Normalizes
Linical Co., Ltd. has secured a large new order from a U.S. biotechnology company worth 20.4 million dollars, or 3,212 million yen, reinforcing its role as a key clinical development partner in the global life sciences market. The mandate follows a p...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 18, 2026
